Kayentis

Global provider of eCOA and patient-centric solutions

Infography to find out how to switch from COA to eCOA

kayentis · Thursday, July 7th, 2016

Infography COA to eCOA: in many cases this move from COA to eCOA generates cost cuts for the sponsor as well, by reducing drastically spendings on monitoring, data management, logistics and non-quality impacts; if the instruments chosen bear study endpoints, the increase of data quantity and quality would in itself justify the switch to eCOA.

For a successful switch from paper (COA) to electronic clinical studies (eCOA), consider 7 major aspects early enough. All of them are detailed in the infography below. Click here to know more about this switch.


How to Switch
from COA to eCOA?
The increase of data quantity and quality would in itself justify the switch to eCOA. For a successful switch from paper to electronic, consider these elements early enough.
Choose the device
that matches your study details
Adapt your device to your
targeted subjects
Manage the transition
from paper to electronic versions
Define the backup
Adapt processes to secure
source data
Think beyond eCOA
www.kayentis.com - Follow us
kayentis
Dedicated to eCOA & Patient Engagement

Several vendors now propose eICF on top of eCOA on the same device for instance, generating savings for the sponsor while making it very simple for the sites and really informative for the subjects.
Moving forward towards eCOA is undoubtedly beneficial to the quality of the data and the trial, and implementation of eCOA solutions is expected to grow quickly in the next few years. In order to smoothly manage this transition, sponsors should strongly consider early work with translation companies and eCOA vendors to cope with the aforementioned challenges.

If you want to know more about our eCOA solutions and expertise, feel free to contact us. We will be glad to share any information about our experience with you.

Guillaume JUGE, CEO – Kayentis

This entry was posted on Thursday, July 7th, 2016 at 12:22 pm and is filed under Optimizing clinical trials
You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.